Among all NHL subtypes, DLBCL is the most common subtype reported globally (1,457, 57.9% in our study) and is typically treated using combination chemotherapy including CHOP and R-CHOP. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.